Title of article :
Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way
Author/Authors :
Yue، نويسنده , , Bin and Zhang، نويسنده , , Yu-Sheng and Xu، نويسنده , , Huimin and Zhao، نويسنده , , Cui-Rong and Li، نويسنده , , Yuanyuan and Qin، نويسنده , , Yi-Zhuo and Wang، نويسنده , , Rui-Qi and Sun، نويسنده , , Di and Yuan، نويسنده , , Yi and Lou، نويسنده , , Hong-Xiang and Qu، نويسنده , , Xian-Jun، نويسنده ,
Abstract :
Riccardin D-26 is a synthesized macrocyclic bisbibenzyl compound. We investigated the effect of Riccardin D-26 on human hepatocellular carcinomas. Riccardin D-26 possessed stronger activity against SMMC-7721 cells than human normal liver cells. Riccardin D-26 injection effectively delayed the growth of SMMC-7721 xenografts in mice without significant toxicity. This effect of Riccardin D-26 was associated with the status of p53 and its targets, bax and p21Waf1/Cip1. Riccardin D-26 activated p53 expression and induced cancer cells to apoptosis through the p53-mediated transcription-dependent and -independent pathway. Overall, Riccardin D-26 may inhibit hepatocellular carcinoma growth through induction of apoptosis in p53-dependent pathway.
Keywords :
Macrocyclic bisbibenzyls , Synthesized Riccardin D , hepatocellular carcinoma , apoptosis , p53-Dependent pathway
